Fetal stem cells inhaled to fight COPD?

NCT ID NCT07477600

Recruiting now Disease control Sponsor: Shenzhen Geno-Immune Medical Institute Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-stage trial is testing whether infusions of clonal fetal mesenchymal stem cells (cfMSCs) are safe and can help control severe symptoms in people with moderate to severe COPD. About 30 adults aged 40-80 who have not responded well to standard treatments will receive the cells. The main goal is to check for side effects, and researchers will also measure changes in lung function.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: clonal fetal mesenchymal stem cells (cfMSCs)
What this could lead to: If it works, this could point toward a new way to control COPD symptoms and improve lung function for people who don't respond to standard treatments.
What could go wrong: This is a very early (Phase 1/2) trial with only 30 people, so it's mainly checking safety. The stem cells are experimental, and it's unknown if they will provide lasting benefit or cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

Contacts and locations

Locations

Shenzhen Geno-immune Medical Institute
RECRUITING

Shenzhen, Guangdong, 518000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.